<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306227</url>
  </required_header>
  <id_info>
    <org_study_id>PHRCIR07-DR-TOURNEUX</org_study_id>
    <nct_id>NCT01306227</nct_id>
  </id_info>
  <brief_title>L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Hypothyroxinemia</brief_title>
  <official_title>L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Transient Hypothyroxinemia of Prematurity: a Prospective Randomized Double-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transient hypothyroxinemia of prematurity (THOP) is associated with neurodevelopmental
      impairment in preterm newborns &lt; 32 weeks of gestation (WG). It is not known whether
      L-Thyroxine supplementation for preterm newborns &lt;32 WG with THOP is beneficial.

      The purpose of this study is to compare L-thyroxine treatment vs. placebo in newborn less
      than 32 WG with THOP.

      The primary endpoint is the neurodevelopmental outcome at two years of life, assessed by the
      Brunet-Lézine score. The secondary endpoints are: death, bronchopulmonary dysplasia (oxygen
      therapy at 28 days of life and at 36 weeks of postnatal age), patent ductus arteriosus, shock
      requiring fluid loading or vasoactive treatments, enterocolitis, intraventricular hemorrhage,
      retinopathy of prematurity, deafness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preterm newborns &lt;32 weeks of gestation (WG) are screened for THOP between day 5 and day 7 of
      life. THOP is defined by thyroid-stimulating hormone (TSH) &lt; 20 mIU/L and FT4 &lt; 0.80 ng/dL.
      After obtaining written consent from the parents, preterm newborns &lt;32 WG with THOP will be
      included. Randomization is stratified by center and 2 age-groups (24-28 WG and 29-32 WG). One
      arm will receive L-thyroxine treatment and the other arm will receive placebo. Treatment will
      be started within one week after diagnosis and will last 6 weeks. TSH and FT4 will be assayed
      2 weeks after stopping treatment.

      The primary endpoint is the neurodevelopmental outcome at two years of life, assessed by the
      Brunet-Lézine score.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2006</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurodevelopmental outcome</measure>
    <time_frame>2 years old</time_frame>
    <description>Brunet-Lézine score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morbidity associated with management of newborns &lt; 32 WG with hypothyroxinemia</measure>
    <time_frame>discharge, 1 year, 2 years</time_frame>
    <description>Death
Bronchopulmonary dysplasia (oxygen therapy at 28 days of life and at 36 weeks of postnatal age)
Patent ductus arteriosus,
Shock requiring fluid loading or vasoactive treatments
Enterocolitis
Intraventricular hemorrhage
Retinopathy of prematurity
Deafness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hypothyroxinemia</condition>
  <arm_group>
    <arm_group_label>water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral treatment with water for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-Thyroxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral treatment with L-Thyroxine for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Thyroxine</intervention_name>
    <description>Treatment with L-Thyroxine:7,5 µg/kg/day. Oral treatment (one drop =5µg) in the morning, once a day.</description>
    <arm_group_label>L-Thyroxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>water</intervention_name>
    <description>Oral treatment with water. Equal number of drop of water as compared with the treatment arm (according to the body weight of the newborn) in the morning, once a day.</description>
    <arm_group_label>water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age &lt; 32 WG

          -  FT4 (5, 6 or 7 days of life) ≤ 0.8 ng/dL

          -  TSH (5, 6 or 7 days of life) &lt; 20 mIU/L

          -  Written consent from the parents

        Exclusion Criteria:

          -  Maternal thyroid disease

          -  FT4 (5, 6 or 7 days of life) &gt; 0.8 ng/dL

          -  TSH (5, 6 or 7 days of life) &gt; 20 mIU/L

          -  Grade III or IV intracerebral hemorrhage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Tourneux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amiens University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <state>Basse Normandie</state>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lens Hospital</name>
      <address>
        <city>Lens</city>
        <state>Nord- Pas De Calais</state>
        <zip>62307</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amiens University Hospital</name>
      <address>
        <city>Amiens</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>February 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2011</study_first_posted>
  <last_update_submitted>August 9, 2018</last_update_submitted>
  <last_update_submitted_qc>August 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infant, newborn</keyword>
  <keyword>Infant, preterm</keyword>
  <keyword>Thyroid</keyword>
  <keyword>Outcome</keyword>
  <keyword>Newborns less than 32 weeks of gestation</keyword>
  <keyword>TSH &lt; 20 mIU/L and a FT4 &lt; 0.80 ng/dL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

